Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Cardiovascular diseases (CVDs) are the leading causes of death worldwide. Epicardial adipose tissue (EAT) is defined as a fat depot localized between the myocardial surface and the visceral layer of the pericardium and is a type of visceral fat. EAT is one of the most important risk factors for atherosclerosis and cardiovascular events and a promising new therapeutic target in CVDs. In health conditions, EAT has a protective function, including protection against hypothermia or mechanical stress, providing myocardial energy supply from free fatty acid and release of adiponectin. In patients with obesity, metabolic syndrome, or diabetes mellitus, EAT becomes a deleterious tissue promoting the development of CVDs. Previously, we showed an adverse modulation of gene expression in pericoronary adipose tissue in patients with coronary artery disease (CAD). Here, we summarize the currently available evidence regarding the role of EAT in the development of CVDs, including CAD, heart failure, and atrial fibrillation. Due to the rapid development of the COVID-19 pandemic, we also discuss data regarding the association between EAT and the course of COVID-19. Finally, we present the potential therapeutic possibilities aiming at modifying EAT’s function. The development of novel therapies specifically targeting EAT could revolutionize the prognosis in CVDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175 · cited 1×
“Cardiovascular diseases (CVDs) remain one of the leading causes of death worldwide [1,2], entailing enormous costs for healthcare systems [3].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Interest in antidiabetic drugs particularly increased after the publication of the results of the EMPA-REG and LEADER trials, which showed that SGLT2 inhibitors and glucagon-like peptide-1 receptor (GLP-1) agonists could have a cardioprotective effect by a mechanism independent of blood glucose level reduction [182,18…”
ResultAbdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159 · cited 1×
“The benefits of adding colchicine to standard therapy were also shown in COLCOT study, which included patients with a history of MI within the last month [243].”
MethodColchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299 · cited 2×
“In LoDoCo2 study, a significant reduction in the primary composite endpoint of cardiovascular death, nonprocedural MI, ischemic stroke, or ischemia-driven coronary revascularization was achieved in colchicine group, compared to the placebo [242].”
BackgroundHuman epicardial adipose tissue is a source of inflammatory mediators
Mazurek, T., Zhang, L., Zalewski, A., Mannion, J. D., Diehl, J. T., Arafat, H., Sarov-Blat, L., O’Brien, S., Keiper, E. A., Johnson, A. G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000099542.57313.c5 · Cited by 1,966 · cited 3×
“EAT is located between the pericardium and the myocardium [5] and is not separated from the myocardium and vessels by fascia, allowing paracrine or vasocrine effects [16] via cytokines and chemokines [17].”
BackgroundLow-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317 · cited 1×
“In the CIRT study that investigated the benefits of methotrexate on outcomes in patients with a history of acute coronary syndrome, MI, and diabetes or metabolic syndrome, no benefits regarding the composite endpoint including nonfatal MI, nonfatal stroke, and cardiovascular death were shown [240].”
Background
Cited by
Obesity and cardiovascular health
Welsh, A., Hammad, M., Piña, I. L., & Kulinski, J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae025 · Cited by 239
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01738-2 · Cited by 93
Ahmad, Y., Seo, D. S., & Jang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137076 · Cited by 49
“The vital role of epicardial adipose tissue is to secrete adiponectin from epicardial adipocytes [102].”
Background
Metadata
- Authors
- Konwerski, M., Gąsecka, A., Opolski, G., Grabowski, M., & Mazurek, T.
- Venue
- Biology
- Publisher
- MDPI AG
- Published
- 2022-02-23
- Volume
- 11
- Issue
- 3
- Pages
- 355
- ISSN
- 2079-7737 (ISSN-L)
- OpenAlex
- W4213127021
- Cited by
- 118
- References
- 59
- FWCI
- 18.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review. https://app.cochat.ai/papers/10.3390/biology11030355
- The paper
- Konwerski, M., Gąsecka, A., Opolski, G., Grabowski, M., & Mazurek, T. (2022). Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review. Biology. https://doi.org/10.3390/biology11030355
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.